Edition:
United Kingdom

Allena Pharmaceuticals Inc (ALNA.OQ)

ALNA.OQ on NASDAQ Stock Exchange Global Select Market

6.77USD
7:25pm GMT
Change (% chg)

$-0.18 (-2.59%)
Prev Close
$6.95
Open
$6.94
Day's High
$7.10
Day's Low
$6.77
Volume
11,220
Avg. Vol
10,403
52-wk High
$17.55
52-wk Low
$4.94

Latest Key Developments (Source: Significant Developments)

Allena Pharmaceuticals Appoints Louis Brenner As Chief Executive Officer
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS ANNOUNCES APPOINTMENT OF LOUIS BRENNER, M.D. AS CHIEF EXECUTIVE OFFICER AND CONFIRMS KEY MILESTONES FOR 2019.ALLENA PHARMACEUTICALS INC - BRENNER WILL SUCCEED ALEXEY MARGOLIN.ALLENA PHARMACEUTICALS INC - ALEXEY MARGOLIN WILL TRANSITION TO CHAIRMAN OF BOARD EFFECTIVE FEBRUARY 1, 2019.  Full Article

Allena Pharma Achieves Alignment With FDA On Phase 3 Program For Reloxaliase
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS ACHIEVES ALIGNMENT WITH FDA ON PHASE 3 PROGRAM AND ACCELERATED APPROVAL PATHWAY FOR RELOXALIASE IN ENTERIC HYPEROXALURIA.ALLENA PHARMACEUTICALS INC - URIROX-2, SECOND PIVOTAL PHASE 3 TRIAL, INITIATED IN Q4 OF 2018.ALLENA PHARMACEUTICALS INC - URIROX-1, FIRST PIVOTAL PHASE 3 TRIAL, ENROLLING; TOPLINE DATA EXPECTED IN SECOND HALF OF 2019.ALLENA PHARMACEUTICALS INC - PRIMARY EFFICACY ENDPOINT OF CHANGE IN URINARY OXALATE EXCRETION AT FOUR WEEKS.  Full Article

Allena Pharmaceuticals Inc files for mixed shelf of upto $200 million - SEC filing
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Allena Pharmaceuticals reports third quarter results
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.46.Q3 EARNINGS PER SHARE VIEW $-0.47 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, CASH AND CASH EQUIVALENTS WERE $70.6 MILLION.EXPECTS EXISTING CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATING EXPENSES, CAPITAL REQUIREMENTS INTO 2020.  Full Article

Allena Pharmaceuticals Reports Q2 Loss Per Share $0.42
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.42.Q2 EARNINGS PER SHARE VIEW $-0.40 -- THOMSON REUTERS I/B/E/S.PLAN TO INITIATE URIROX-2™ IN 2H18.REITERATES GUIDANCE.ALLENA PHARMACEUTICALS - EXPECT CASH, CASH EQUIVALENTS TO BE SUFFICIENT TO FUND OPERATING. EXPENSES , CAPITAL REQUIREMENTS INTO 2020.  Full Article

Allena Pharmaceuticals Inc - First Patients Treated In Phase 2 Basket Study Of ALLN-177
Monday, 23 Jul 2018 

July 23 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS INC - FIRST PATIENTS TREATED IN PHASE 2 BASKET STUDY OF ALLN-177.  Full Article

Allena Pharmaceuticals Reports Q1 Loss Per Share $0.38
Tuesday, 8 May 2018 

May 8 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.38.Q1 EARNINGS PER SHARE VIEW $-0.43 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENTS WERE $86.4 MILLION, VERSUS $94.5 MILLION AS OF DECEMBER 31, 2017.CONTINUES TO EXPECT EXISTING CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2020.  Full Article

Allena Pharma Reports Q3 Loss Per Share $3.49
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $3.49.Q3 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.  Full Article

HBM BioCapital II reports 7.94 pct passive stake in Allena Pharma
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Allena Pharmaceuticals Inc :HBM BioCapital II LP reports 7.94 percent passive stake in Allena Pharmaceuticals Inc as of November 6, 2017 - SEC filing‍​.  Full Article

Allena Pharmaceuticals shares open 14.3 pct below IPO price in debut
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - :Allena Pharmaceuticals shares open at $12 in debut on the NASDAQ versus IPO price of $14/shr‍​.  Full Article